{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:08:43Z","timestamp":1768529323190,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40272-019-00354-6","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T05:03:05Z","timestamp":1566968585000},"page":"389-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6234-822X","authenticated-orcid":false,"given":"Rabia Miray","family":"Kisla Ekinci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-313X","authenticated-orcid":false,"given":"Sibel","family":"Balci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3972-7277","authenticated-orcid":false,"given":"Dilek","family":"Dogruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-5248","authenticated-orcid":false,"given":"Derya Ufuk","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6213-8289","authenticated-orcid":false,"given":"Mustafa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"354_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(97)09408-7","volume":"351","author":"E Ben-Chetrit","year":"1998","unstructured":"Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659\u201364.","journal-title":"Lancet"},{"key":"354_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00296-017-3796-0","volume":"38","author":"K Barut","year":"2018","unstructured":"Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G, Pamuk G, Ayd\u0131n AK, Dasdemir S, Turanl\u0131 ET, Buyru N, Kasapcopur O. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int. 2018;38:67\u201374.","journal-title":"Rheumatol Int"},{"key":"354_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644\u201351.","journal-title":"Ann Rheum Dis"},{"key":"354_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.5606\/ArchRheumatol.2018.6488","volume":"33","author":"RM Kisla Ekinci","year":"2017","unstructured":"Kisla Ekinci RM, Balci S, Ufuk Altinta\u015f D, Yilmaz M. The influence of concomitant disorders on disease severity of familial Mediterranean fever in children. Arch Rheumatol. 2017;33:282\u20137.","journal-title":"Arch Rheumatol."},{"key":"354_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jclinpath-2016-203810","volume":"70","author":"S Pathak","year":"2017","unstructured":"Pathak S, McDermott MF, Savic S. Autoinflammatory diseases: update on classification diagnosis and management. J Clin Pathol. 2017;70:1\u20138.","journal-title":"J Clin Pathol"},{"key":"354_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.immuni.2011.02.020","volume":"34","author":"JJ Chae","year":"2011","unstructured":"Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1\u03b2 activation and severe autoinflammation in mice. Immunity. 2011;34:755\u201368.","journal-title":"Immunity"},{"key":"354_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1146\/annurev-immunol-032414-112227","volume":"33","author":"AA de Jesus","year":"2015","unstructured":"de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol. 2015;33:823\u201374.","journal-title":"Annu Rev Immunol"},{"key":"354_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.semarthrit.2010.11.003","volume":"41","author":"U Meinzer","year":"2011","unstructured":"Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kon\u00e9-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41:265\u201371.","journal-title":"Semin Arthritis Rheum"},{"key":"354_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10067-014-2772-2","volume":"35","author":"ZB \u00d6z\u00e7akar","year":"2016","unstructured":"\u00d6z\u00e7akar ZB, \u00d6zdel S, Y\u0131lmaz S, Kurt-\u015e\u00fck\u00fcr ED, Ekim M, Yal\u00e7\u0131nkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35:441\u20136.","journal-title":"Clin Rheumatol"},{"key":"354_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13075-015-0765-4","volume":"17","author":"A G\u00fcl","year":"2015","unstructured":"G\u00fcl A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243.","journal-title":"Arthritis Res Ther."},{"key":"354_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10753-014-0004-1","volume":"38","author":"P Cetin","year":"2015","unstructured":"Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever. Inflammation. 2015;38:27\u201331.","journal-title":"Inflammation"},{"key":"354_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40348-016-0058-2","volume":"3","author":"B Sozeri","year":"2016","unstructured":"Sozeri B, Gulez N, Ergin M, Serdaroglu E. The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever. Mol Cell Pediatr. 2016;3:33.","journal-title":"Mol Cell Pediatr."},{"key":"354_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3109\/14397595.2014.987437","volume":"25","author":"\u00d6 Ba\u015faran","year":"2015","unstructured":"Ba\u015faran \u00d6, Uncu N, \u00c7elikel BA, Taktak A, G\u00fcr G, Cakar N. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol. 2015;25:621\u20134.","journal-title":"Mod Rheumatol"},{"key":"354_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00296-018-3993-5","volume":"38","author":"F Yaz\u0131l\u0131ta\u015f","year":"2018","unstructured":"Yaz\u0131l\u0131ta\u015f F, Aydo\u011f \u00d6, \u00d6zl\u00fc SG, \u00c7ak\u0131c\u0131 EK, G\u00fcng\u00f6r T, Ero\u011flu FK, et al. Canakinumab treatment in children with familial Mediterranean fever: report from a single center. Rheumatol Int. 2018;38:879\u201385.","journal-title":"Rheumatol Int"},{"key":"354_CR15","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1002\/art.38777","volume":"66","author":"R Brik","year":"2014","unstructured":"Brik R, Butbul-Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz-Minei T, Tseng L, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol. 2014;66:3241\u20133.","journal-title":"Arthritis Rheumatol"},{"key":"354_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3899\/jrheum.160518","volume":"44","author":"K Laskari","year":"2017","unstructured":"Laskari K, Boura P, Dalekos GN, Garyfallos A, Karokis D, Pikazis D, et al. Long-term beneficial effect of canakinumab in colchicine-resistant familial Mediterranean fever. J Rheumatol. 2017;44:102\u20139.","journal-title":"J Rheumatol"},{"key":"354_CR17","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F De Benedetti","year":"2018","unstructured":"De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908\u201319.","journal-title":"N Engl J Med"},{"key":"354_CR18","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/art.1780401023","volume":"40","author":"A Livneh","year":"1997","unstructured":"Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879\u201385.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"354_CR19","first-page":"75","volume":"4","author":"JCh van der Hilst","year":"2016","unstructured":"van der Hilst JCh, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;4(10):75\u201380.","journal-title":"Biologics."},{"key":"354_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acr.23446","volume":"70","author":"S Akar","year":"2018","unstructured":"Akar S, Cetin P, Kalyoncu U, Karadag O, Sari I, C\u0131nar M, et al. Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients. Arthritis Care Res (Hoboken). 2018;70:1090\u20134.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"354_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000873","author":"H Babaoglu","year":"2018","unstructured":"Babaoglu H, Varan O, Kucuk H, Atas N, Satis H, Salman R, et al. Effectiveness of canakinumab in colchicine- and anakinra-resistant or -intolerant adult familial Mediterranean fever patients: A single-center real-life study. J Clin Rheumatol. 2018. \n                    https:\/\/doi.org\/10.1097\/RHU.0000000000000873\n                    \n                  .","journal-title":"J Clin Rheumatol."},{"issue":"5","key":"354_CR22","doi-asserted-by":"publisher","first-page":"e20180948","DOI":"10.1542\/peds.2018-0948","volume":"142","author":"Rabia Miray Kisla Ekinci","year":"2018","unstructured":"Kisla Ekinci RM, Balci S, Bisgin A, Hershfield M, Atmis B, Dogruel D, et al. Renal amyloidosis in deficiency of adenosine deaminase 2: successful experience with canakinumab. Pediatrics. 2018;142(5):e20180948.","journal-title":"Pediatrics"},{"key":"354_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1590\/1516-3180.2018.0311101218","volume":"137","author":"G Sargin","year":"2019","unstructured":"Sargin G, Kose R, Senturk T. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis. Sao Paulo Med J. 2019;137:39\u201344.","journal-title":"Sao Paulo Med J."},{"key":"354_CR24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/14397595.2016.1194510","volume":"27","author":"O Kucuksahin","year":"2017","unstructured":"Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever. Mod Rheumatol. 2017;27:350\u20135.","journal-title":"Mod Rheumatol"},{"key":"354_CR25","first-page":"1991","volume":"25","author":"RE Petty","year":"1998","unstructured":"Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25:1991\u20134.","journal-title":"J Rheumatol"},{"key":"354_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 2019;71:846\u201363.","journal-title":"Arthritis Rheumatol."},{"key":"354_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2474-12-153","volume":"12","author":"R Alten","year":"2011","unstructured":"Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, et al. Efficacy and safety of the human anti-IL-1\u03b2 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord. 2011;12:153.","journal-title":"BMC Musculoskelet Disord."},{"key":"354_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2018.1559488","volume":"17","author":"N G\u00fclez","year":"2018","unstructured":"G\u00fclez N, Makay B, S\u00f6zeri B. Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients. Mod Rheumatol. 2018;17:1\u201313.","journal-title":"Mod Rheumatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-019-00354-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T23:10:32Z","timestamp":1598483432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-019-00354-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1007\/s40272-019-00354-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"28 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr Kisla Ekinci, Dr Sibel Balci, Dr Dilek Dogruel, Dr Derya Ufuk Altintas, and Dr Mustafa Yilmaz declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from parents of the participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}